RE: Cohort 727 Feb 2024 14:23
From 13 Dec RNS
4. The next steps with AVA6000 involve optimising the patient population, dose and schedule in order to increase efficacy and tolerability of doxorubicin treatment via pre|CISIONTM targeting. Given the favourable safety data from the three-weekly dosing study, a fortnightly dosing study, which is now screening patients with high FAP levels in the United States, will assist in optimising the schedule and dose for a potentially pivotal Phase 2 study in 2024.
A) It says 'which is now screening' so screening may have only just started a day or so before this RNS. There is no indication as to how long screening has been taking place.
b) Screening is not the start of the dosing...there was Christmas/New Year to consider, the trial set up and the FDA approvals/guidlines.
c) We are only 27 February and there is not reason to believe (IMO) that they are running late if we are only going to get news when the 3rd patient has been dosed.
There are a lot of players when it comes to setting up this new trial and just because we want things to move along quickly, it doesn't mean they do necessarily. Because efficacy was observed in what was a safety 3 week trial, Avacta now have the potental of a much quicker route to market timeframe after consulting with the FDA. This 2 week trial is the huge key...if strong efficacy is observed with little or no side effects is observed it will blow the doors off our pipeline cabinet.
If I was an interested party, I would not want to let anyone else see the 2 weekly data before me...would you?
Why 3rd patient dosed? Why not 1st or 2nd or last?
Just gotta wait a little longer guys....
Sign In
Follow the stocks
